Amorphous solid dispersions: Rational selection of a manufacturing process

Advanced Drug Delivery Reviews

Volumn 100, Issue , 2016, Pages 85-101

  Vasconcelos, Teófilo ^a,b,c,d   Marques, Sara ^e   das Neves, José ^c,d   Sarmento, Bruno ^c,d,f  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^e CENTRO DE INVESTIGAÇÃO EM BIODIVERSIDADE E RECURSOS GENÉTICOS   (Portugal)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Amorphous products; Drug delivery; Industrial scale; Laboratorial scale; Melting process; Solid dispersions; Solvent evaporation process

Indexed keywords

AMORPHOUS MATERIALS; DRUG DELIVERY; DRUG PRODUCTS; EVAPORATION; MANUFACTURE; MELTING; METAL MELTING;

INDUSTRIAL SCALE; LABORATORIAL SCALE; MELTING PROCESS; SOLID DISPERSION; SOLVENT EVAPORATION;

DISPERSIONS;

ATORVASTATIN; CEFUROXIME AXETIL; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; DIAZEPAM; DIMENHYDRINATE; DULOXETINE; ETRAVIRINE; EVEROLIMUS; FENOFIBRATE; GRISEOFULVIN; ITRACONAZOLE; IVACAFTOR; LOPINAVIR; LUMACAFTOR; METFORMIN; NABILONE; OMBITASVIR; PARITAPREVIR; POSACONAZOLE; RITONAVIR; ROSUVASTATIN; TACROLIMUS; TELAPREVIR; TOLVAPTAN; UNINDEXED DRUG; VEMURAFENIB; VILDAGLIPTIN; ZAFIRLUKAST;

DISPERSION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; FREEZE DRYING; GOOD MANUFACTURING PRACTICE; MELTING POINT; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SPRAY DRYING; BIOAVAILABILITY; MEDICINAL CHEMISTRY; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; REPRODUCIBILITY OF RESULTS; SOLUBILITY;

EID: 84957916380     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.012     Document Type: Review

References (196)

1. Ku M.S. Use of the biopharmaceutical classification system in early drug development. AAPS J. 2008, 10:208-212.
2. Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J. 2011, 13:519-547.
3. Borhani D.W., Shaw D.E. The future of molecular dynamics simulations in drug discovery. J. Comput. Aided Mol. Des. 2012, 26:15-26.
4. Marshall G.R. Computer-aided drug design. Annu. Rev. Pharmacol. Toxicol. 1987, 27:193-213.
5. Kawakami K. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J. Pharm. Sci. 2009, 98:2875-2885.
6. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
7. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
8. Ku M.S., Dulin W. A biopharmaceutical classification-based right-first-time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-In-human to clinical proof-of-concept. Pharm. Dev. Technol. 2012, 17:285-302.
9. Streubel A., Siepmann J., Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacol. 2006, 6:501-508.
10. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., Dahlin A., Evers R., Fischer V., Hillgren K.M., Hoffmaster K.A., Ishikawa T., Keppler D., Kim R.B., Lee C.A., Niemi M., Polli J.W., Sugiyama Y., Swaan P.W., Ware J.A., Wright S.H., Yee S.W., Zamek-Gliszczynski M.J., Zhang L. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9:215-236.
11. Cutler L., Howes C., Deeks N.J., Buck T.L., Jeffrey P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J. Pharm. Sci. 2006, 95:1944-1953.
12. Seo J.H., Park J.B., Choi W.K., Park S., Sung Y.J., Oh E., Bae S.K. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. Drug Des. Devel. Ther. 2015, 9:3961-3968.
13. Novozhilov Y.V., Dorogov M.V., Blumina M.V., Smirnov A.V., Krasavin M. An improved kilogram-scale preparation of atorvastatin calcium. Chem. Cent. J. 2015, 9:7.
14. Sarkar A., Rohani S. Molecular salts and co-crystals of mirtazapine with promising physicochemical properties. J. Pharm. Biomed. Anal. 2015, 110:93-99.
15. Serrano D.R., Gallagher K.H., Healy A.M. Emerging nanonisation technologies: tailoring crystalline versus amorphous nanomaterials. Curr. Top. Med. Chem. 2015, 15:2327-2340.
16. Zhang Z.H., Zhang Q., Zhang Q.Q., Chen C., He M.Y., Chen Q., Song G.Q., Xuan X.P., Huang X.F. From a binary salt to salt co-crystals of antibacterial agent lomefloxacin with improved solubility and bioavailability. Acta Crystallogr. Sect. B: Struct. Sci. Cryst. Eng. Mater. 2015, 71:437-446.
17. Chadha R., Bhandari S., Khullar S., Mandal S.K., Jain D.V. Characterization and evaluation of multi-component crystals of hydrochlorothiazide. Pharm. Res. 2014, 31:2479-2489.
18. Weuts I., Kempen D., Verreck G., Peeters J., Brewster M., Blaton N., Van den Mooter G. Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage. Eur. J. Pharm. Sci. 2005, 25:387-393.
19. Seefeldt K., Miller J., Alvarez-Núñez F., Rodríguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J. Pharm. Sci. 2007, 96:1147-1158.
20. Dimopoulou M., Mourouti C.S., Vertzoni M., Symillides M., Reppas C. In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts. J. Pharm. Pharmacol. 2015.
21. Terebetski J.L., Cummings J.J., Fauty S.E., Michniak-Kohn B. Combined use of crystalline sodium salt and polymeric precipitation inhibitors to improve pharmacokinetic profile of ibuprofen through supersaturation. AAPS PharmSciTech 2014, 15:1334-1344.
22. Sai Gouthami K., Kumar D., Thipparaboina R., Chavan R.B., Shastri N.R. Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol. Int. J. Pharm. 2015, 491:26-34.
23. Bhakay A., Merwade M., Bilgili E., Dave R.N. Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev. Ind. Pharm. 2011, 37:963-976.
24. Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 2006, 29:278-287.
25. Prabhu S., Ortega M., Ma C. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int. J. Pharm. 2005, 301:209-216.
26. Gupta S., Kesarla R., Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm. 2013, 2013:848043.
27. Laitinen R., Löbmann K., Strachan C.J., Grohganz H., Rades T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 2013, 453:65-79.
28. Karolewicz B., Górniak A., Owczarek A., Nartowski K., Zurawska-Płaksej E., Pluta J. Solid dispersion in pharmaceutical technology. part II. the methods of analysis of solid dispersions and examples of their application. Polim. Med. 2012, 42:97-107.
29. Lee E.H. A practical guide to pharmaceutical polymorph screening & selection. Asian J. Pharm. Sci. 2014, 9:163-175.
30. Murshedkar T. Effect of Crystalline to Amorphous Conversions on Solubility of Cefuroxime Axetil 2002, University of Rhode Island.
31. Tawa M., Almarsson O., Remenar J. Pharmaceutical Salts of Zafirlukast, Google Patents 2005.
32. Pastrano G., Ghaly E. Physicochemical characterization of spray dried formulation containing amorphous drug. Int. J. Pharm. Pharm. Sci. 2012, 4:563-570.
33. Talaczyńska A., Lewandowska K., Jelińska A., Garbacki P., Podborska A., Zalewski P., Oszczapowicz I., Sikora A., Kozak M., Cielecka-Piontek J. Application of vibrational spectroscopy supported by theoretical calculations in identification of amorphous and crystalline forms of cefuroxime axetil. Sci. World J. 2015, 2015:921049.
34. Jelińska A., Dudzińska I., Zajac M., Oszczpowicz I. The stability of the amorphous form of cefuroxime axetil in solid state. J. Pharm. Biomed. Anal. 2006, 41:1075-1081.
35. Urbanetz N.A. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur. J. Pharm. Sci. 2006, 28:67-76.
36. Tanaka N., Imai K., Okimoto K., Ueda S., Tokunaga Y., Ohike A., Ibuki R., Higaki K., Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J. Control. Release 2005, 108:386-395.
37. Vilhelmsen T., Eliasen H., Schfer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int. J. Pharm. 2005, 303:132-142.
38. Karata A., Yksel N., Baykara T. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol. Farmaco 2005, 60:777-782.
39. Damian F., Blaton N., Naesens L., Balzarini J., Kinget R., Augustijns P., Van den Mooter G. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14. Eur. J. Pharm. Sci. 2000, 10:311-322.
40. Vasconcelos T., Barrocas P., Lima R., Soares-da-Silva P. Development of An Opicapone Third Generation Solid Dispersion. 2013 AAPS Annual MeetingSan Antonio, USA 2013.
41. He Y., Ho C. Amorphous solid dispersions: utilization and challenges in drug discovery and development. J. Pharm. Sci. 2015, 104:3237-3258.
42. Nielsen L.H., Rades T., Müllertz A. Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. Int. J. Pharm. 2015, 490:334-340.
43. Vo C.L., Park C., Lee B.J. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 2013, 85:799-813.
44. Huang Y., Dai W.-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. APSB 2014, 4:18-25.
45. Lin Y., Cogdill R.P., Wildfong P.L. Informatic calibration of a materials properties database for predictive assessment of mechanically activated disordering potential for small molecule organic solids. J. Pharm. Sci. 2009, 98:2696-2708.
46. Sóti P.L., Bocz K., Pataki H., Eke Z., Farkas A., Verreck G., Kiss É., Fekete P., Vigh T., Wagner I., Nagy Z.K., Marosi G. Comparison of spray drying, electroblowing and electrospinning for preparation of eudragit E and itraconazole solid dispersions. Int. J. Pharm. 2015, 494:23-30.
47. Passerini N., Calogerà G., Albertini B., Rodriguez L. Melt granulation of pharmaceutical powders: a comparison of high-shear mixer and fluidised bed processes. Int. J. Pharm. 2010, 391:177-186.
48. Homayouni A., Sadeghi F., Nokhodchi A., Varshosaz J., Afrasiabi Garekani H. Preparation and characterization of celecoxib dispersions in Soluplus(®): comparison of spray drying and conventional methods. Iran J. Pharm. Res. 2015, 14:35-50.
49. Potter C., Tian Y., Walker G., McCoy C., Hornsby P., Donnelly C., Jones D.S., Andrews G.P. Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion. Mol. Pharm. 2015, 12:1377-1390.
50. Won D.-H., Kim M.-S., Lee S., Park J.-S., Hwang S.-J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int. J. Pharm. 2005, 301:199-208.
51. Dhirendra K., Lewis S., Udupa N., Atin K. Solid dispersions: a review. Pak. J. Pharm. Sci. 2009, 22:234-246.
52. Taylor L.S., Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 1997, 14:1691-1698.
53. Repka M.A., Shah S., Lu J., Maddineni S., Morott J., Patwardhan K., Mohammed N.N. Melt extrusion: process to product. Expert Opin. Drug Deliv. 2012, 9:105-125.
54. Paudel A., Worku Z.A., Meeus J., Guns S., Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int. J. Pharm. 2013, 453:253-284.
55. Patil H., Tiwari R.V., Repka M.A. Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech 2015.
56. Ha E.S., Baek I.H., Cho W., Hwang S.J., Kim M.S. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. Chem. Pharm. Bull.(Tokyo) 2014, 62:545-551.
57. Xie T., Taylor L. Dissolution performance of high drug loading celecoxib amorphous solid dispersions formulated with polymer combinations. Pharm. Res. 2015, 1-12.
58. Fong S.Y.K., Ibisogly A., Bauer-Brandl A. Solubility enhancement of BCS class II drug by solid phospholipid dispersions: spray drying versus freeze-drying. Int. J. Pharm. 2015, 496:382-391.
59. Park J.H., Choi H.K. Enhancement of solubility and dissolution of cilostazol by solid dispersion technique. Arch. Pharm. Res. 2015, 38:1336-1344.
60. Kim Y.H., Kim D.W., Kwon M.S., Cho K.H., Kim J.O., Yong C.S., Choi H.-G. Clopidogrel napadisilate monohydrate loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation. Biol. Pharm. Bull. 2015, 38:1033-1040.
61. van Drooge D.J., Hinrichs W.L.J., Visser M.R., Frijlink H.W. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 2006, 310:220-229.
62. Desai J., Alexander K., Riga A. Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release. Int. J. Pharm. 2006, 308:115-123.
63. Lim S.M., Pang Z.W., Tan H.Y., Shaikh M., Adinarayana G., Garg S. Enhancement of docetaxel solubility using binary and ternary solid dispersion systems. Drug Dev. Ind. Pharm. 2015, 1-9.
64. Karavas E., Ktistis G., Xenakis A., Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur. J. Pharm. Biopharm. 2006, 63:103-114.
65. Sanganwar G.P., Gupta R.B. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int. J. Pharm. 2008, 360:213-218.
66. Pestieau A., Krier F., Lebrun P., Brouwers A., Streel B., Evrard B. Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation. Int. J. Pharm. 2015, 485:295-305.
67. Yoshihashi Y., Iijima H., Yonemochi E., Terada K. Estimation of physical stability of amorphous solid dispersion using differential scanning calorimetry. J. Therm. Anal. Calorim. 2006, 85:689-692.
68. Censi R., Gigliobianco M., Dubbini A., Malaj L., Di Martino P. New nanometric solid dispersions of glibenclamide in Neusilin® UFL2. AAPS PharmSciTech 2015, 1-9.
69. Higashi K., Hayashi H., Yamamoto K., Moribe K. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate. Int. J. Pharm. 2015, 494:9-16.
70. Tabbakhian M., Hasanzadeh F., Tavakoli N., Jamshidian Z. Dissolution enhancement of glibenclamide by solid dispersion: solvent evaporation versus a supercritical fluid-based solvent-antisolvent technique. Res. Pharm. Sci. 2014, 9:337-350.
71. Sui X., Wei W., Yang L., Zu Y., Zhao C., Zhang L., Yang F., Zhang Z. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. Int. J. Pharm. 2012, 423:471-479.
72. Purohit H.S., Taylor L.S. Miscibility of itraconazole-hydroxypropyl methylcellulose blends: insights with high resolution analytical methodologies. Mol. Pharm. 2015, 12:4542-4553.
73. Yin X., Daintree L.S., Ding S., Ledger D.M., Wang B., Zhao W., Qi J., Wu W., Han J. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs. Drug Des. Devel. Ther. 2015, 9:2801-2810.
74. Ha E.-S., Kim J.-S., Baek I.-h., Yoo J.-W., Jung Y., Moon H.R., Kim M.-S. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process. Drug Des. Devel. Ther. 2015, 9:4269-4277.
75. Singh A., De Bisschop C., Schut H., Van Humbeeck J., Van Den Mooter G. Compression effects on the phase behaviour of miconazole-poly (1-vinylpyrrolidone-co-vinyl acetate) solid dispersions-role of pressure, dwell time, and preparation method. J. Pharm. Sci. 2015, 104:3366-3376.
76. Keratichewanun S., Yoshihashi Y., Sutanthavibul N., Terada K., Chatchawalsaisin J. An investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy. Pharm. Res. 2015, 32:2458-2473.
77. Falconer J.R., Wen J., Zargar-Shoshtari S., Chen J.J., Mohammed F., Chan J., Alany R.G. The effects of supercritical carbon dioxide processing on progesterone dispersion systems: a multivariate study. AAPS PharmSciTech 2012, 13:1255-1265.
78. Li Y., Yang D.J., Chen S.L., Chen S.B., Chan A.S. Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation. Int. J. Pharm. 2008, 359:35-45.
79. Vasconcelos T., Marques S., Sarmento B. Development of a Resveratrol Solid Dispersion with Soluplus®. 2nd Annual Meeting & Exposition of the Controlled Release SocietyEdinburgh, Scotland 2015.
80. Ahuja N., Katare O.P., Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur. J. Pharm. Biopharm. 2007, 65:26-38.
81. Craye G., Löbmann K., Grohganz H., Rades T., Laitinen R. Characterization of amorphous and co-amorphous simvastatin formulations prepared by spray drying. Molecules 2015, 20:19784.
82. Cho Y., Ha E.-S., Baek I.-H., Kim M.-S., Cho C.-W., Hwang S.-J. Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E. Molecules 2015, 20:9496.
83. Wlodarski K., Sawicki W., Kozyra A., Tajber L. Physical stability of solid dispersions with respect to thermodynamic solubility of tadalafil in PVP-VA. Eur. J. Pharm. Biopharm. 2015, 96:237-246.
84. Wlodarski K., Sawicki W., Haber K., Knapik J., Wojnarowska Z., Paluch M., Lepek P., Hawelek L., Tajber L. Physicochemical properties of tadalafil solid dispersions-impact of polymer on the apparent solubility and dissolution rate of tadalafil. Eur. J. Pharm. Biopharm. 2015, 94:106-115.
85. Kim M.S., Baek I.H. Fabrication and evaluation of valsartan-polymer-surfactant composite nanoparticles by using the supercritical antisolvent process. Int. J. Nanomedicine 2014, 9:5167-5176.
86. Yoshida V.M., Balcão V.M., Vila M.M., Oliveira Júnior J.M., Aranha N., Chaud M.V., Gremião M.P. Zidovudine-poly(l-lactic acid) solid dispersions with improved intestinal permeability prepared by supercritical antisolvent process. J. Pharm. Sci. 2015, 104:1691-1700.
87. Milne M., Liebenberg W., Aucamp M. The stabilization of amorphous Zopiclone in an amorphous solid dispersion. AAPS PharmSciTech 2015.
88. Lloyd G.R., Craig D.Q., Smith A. A calorimetric investigation into the interaction between paracetamol and polyethlene glycol 4000 in physical mixes and solid dispersions. Eur. J. Pharm. Biopharm. 1999, 48:59-65.
89. Engers D., Teng J., Jimenez-Novoa J., Gent P., Hossack S., Campbell C., Thomson J., Ivanisevic I., Templeton A., Byrn S., Newman A. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. J. Pharm. Sci. 2010, 99:3901-3922.
90. Shanbhag A., Rabel S., Nauka E., Casadevall G., Shivanand P., Eichenbaum G., Mansky P. Method for screening of solid dispersion formulations of low-solubility compounds-miniaturization and automation of solvent casting and dissolution testing. Int. J. Pharm. 2008, 351:209-218.
91. Muhrer G., Meier U., Fusaro F., Albano S., Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug-polymer solid dispersions. Int. J. Pharm. 2006, 308:69-83.
92. Majerik V., Charbit G., Badens E., Horvath G., Szokonya L., Bosc N., Teillaud E. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. J. Supercrit. Fluids 2007, 40:101-110.
93. Yue H., Nicholson S.J., Young J.D., Hsieh D., Ketner R.J., Hall R.G., Sackett J., Banks E.C., Castoro J.A., Randazzo M.E. Development of a control strategy for benzene impurity in HPMCAS-stabilized spray-dried dispersion drug products using a science-based and risk-based approach. Pharm. Res. 2015, 32:2636-2648.
94. Sinha S., Ali M., Baboota S., Ahuja A., Kumar A., Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010, 11:518-527.
95. Gangurde A.B., Kundaikar H.S., Javeer S.D., Jaiswar D.R., Degani M.S., Amin P.D. Enhanced solubility and dissolution of curcumin by a hydrophilic polymer solid dispersion and its insilico molecular modeling studies. J. Drug Delivery Sci. Technol. 2015, 29:226-237.
96. Drooge D.J.v., Braeckmans K., Hinrichs W.L.J., Remaut K., Smedt S.C.D., Frijlink H.W. Characterization of the mode of incorporation of lipophilic compounds in solid dispersions at the nanoscale using fluorescence resonance energy transfer (FRET). Macromol. Rapid Commun. 2006, 27:1149-1155.
97. Teagarden D.L., Baker D.S. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur. J. Pharm. Sci. 2002, 15:115-133.
98. Pasquali I., Bettini R., Giordano F. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Adv. Drug Deliv. Rev. 2008, 60:399-410.
99. Srinarong P., de Waard H., Frijlink H.W., Hinrichs W.L. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opin. Drug Deliv. 2011, 8:1121-1140.
100. Fattahi A., Karimi-Sabet J., Keshavarz A., Golzary A., Rafiee-Tehrani M., Dorkoosh F.A. Preparation and characterization of simvastatin nanoparticles using rapid expansion of supercritical solution (RESS) with trifluoromethane. J. Supercrit. Fluids 2016, 107:469-478.
101. Girotra P., Singh S.K., Nagpal K. Supercritical fluid technology: a promising approach in pharmaceutical research. Pharm. Dev. Technol. 2013, 18:22-38.
102. Mishima K., Honjo M., Sharmin T., Ito S., Kawakami R., Kato T., Misumi M., Suetsugu T., Orii H., Kawano H., Irie K., Sano K., Harada T., Ouchi M. Gas-saturated solution process to obtain microcomposite particles of alpha lipoic acid/hydrogenated colza oil in supercritical carbon dioxide. Pharm. Dev. Technol. 2015, 1-12.
103. Jiang Q., Li Y., Fu Q., Geng Y., Zhao J., Ma P., Zhang T. In-vitro and in-vivo study of amorphous spironolactone prepared by adsorption method using supercritical CO2. Drug Dev. Ind. Pharm. 2015, 41:201-206.
104. Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H., Hwang S.J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 2008, 69:454-465.
105. Gong K., Viboonkiat R., Rehman I.U., Buckton G., Darr J.A. Formation and characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free supercritical fluid processing. J. Pharm. Sci. 2005, 94:2583-2590.
106. Park J., Park H.J., Cho W., Cha K.H., Kang Y.S., Hwang S.J. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process. Int. J. Pharm. 2010, 396:239-245.
107. Lee S., Nam K., Kim M.S., Jun S.W., Park J.S., Woo J.S., Hwang S.J. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch. Pharm. Res. 2005, 28:866-874.
108. Kikic I., Alessi P., Eva F., Moneghini M., Perissutti B. Supercritical antisolvent precipitation of atenolol: the influence of the organic solvent and of the processing approach. J. Supercrit. Fluids 2006, 38:434-441.
109. Hanna P.Y.M. Method and Apparatus for the Formation of Particles 1995, WO (Ed.).
110. Tres F., Coombes S., Phillips A., Hughes L., Wren S., Aylott J., Burley J. Investigating the dissolution performance of amorphous solid dispersions using magnetic resonance imaging and proton NMR. Molecules 2015, 20:16404.
111. Chan S.-Y., Qi S., Craig D.Q.M. An investigation into the influence of drug-polymer interactions on the miscibility, processability and structure of polyvinylpyrrolidone-based hot melt extrusion formulations. Int. J. Pharm. 2015, 496:95-106.
112. Huang S., O'Donnell K.P., Keen J.M., Rickard M.A., McGinity J.W., Williams R.O. A new extrudable form of hypromellose: AFFINISOL™ HPMC HME. AAPS PharmSciTech 2015.
113. De Jaeghere W., De Beer T., Van Bocxlaer J., Remon J.P., Vervaet C. Hot-melt extrusion of polyvinyl alcohol for oral immediate release applications. Int. J. Pharm. 2015, 492:1-9.
114. Shergill M., Patel M., Khan S., Bashir A., McConville C. Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int. J. Pharm. 2016, 497:3-11.
115. Koh P.T., Chuah J.N., Talekar M., Gorajana A., Garg S. Formulation development and dissolution rate enhancement of efavirenz by solid dispersion systems. Indian J. Pharm. Sci. 2013, 75:291-301.
116. Alhijjaj M., Bouman J., Wellner N., Belton P., Qi S. Creating drug solubilization compartments via phase separation in multicomponent buccal patches prepared by direct hot melt extrusion-injection molding. Mol. Pharm. 2015, 12:4349-4362.
117. Feng X., Vo A., Patil H., Tiwari R.V., Alshetaili A.S., Pimparade M.B., Repka M.A. The effects of polymer carrier, hot melt extrusion process and downstream processing parameters on the moisture sorption properties of amorphous solid dispersions. J. Pharm. Pharmacol. 2015, (n/a-n/a).
118. Maniruzzaman M., Nair A., Scoutaris N., Bradley M.S.A., Snowden M.J., Douroumis D. One-step continuous extrusion process for the manufacturing of solid dispersions. Int. J. Pharm. 2015, 496:42-51.
119. Yuan X., Xiang T.-X., Anderson B.D., Munson E.J. Hydrogen bonding interactions in amorphous indomethacin and its amorphous solid dispersions with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl acetate) studied using 13C solid-state NMR. Mol. Pharm. 2015, 12:4518-4528.
120. Lee J.Y., Kang W.S., Piao J., Yoon I.S., Kim D.D., Cho H.J. Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan. Drug Des. Devel. Ther. 2015, 9:2745-2756.
121. Shalaev E.Y., Lu Q., Shalaeva M., Zografi G. Acid-catalyzed inversion of sucrose in the amorphous state at very low levels of residual water. Pharm. Res. 2000, 17:366-370.
122. Vasconcelos T., costa P. Development of a rapid dissolving Ibuprofen solid dispersion. PSWC-7 Pharmaceutical Sciences World ConferenceAmsterdam, Netherlands 2007.
123. Sekiguchi K., Obi N., Ueda Y. Studies on absorption of eutectic mixture. II. Absorption of fused conglomerates of chloramphenicol and urea in rabbits. Chem. Pharm. Bull.(Tokyo) 1964, 12:134-144.
124. Pokharkar V.B., Mandpe L.P., Padamwar M.N., Ambike A.A., Mahadik K.R., Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol. 2006, 167:20-25.
125. Chiou W.L., Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 1969, 58:1505-1510.
126. Timko R.J., Lordi N.G. Thermal characterization of citric acid solid dispersions with benzoic acid and phenobarbital. J. Pharm. Sci. 1979, 68:601-605.
127. Nagapudi A., Jona J. Amorphous active pharmaceutical ingredients in preclinical studies: preparation, characterization, and formulation. Curr. Bioact. Compd. 2008, 213-224.
128. Vippagunta S.R., Wang Z., Hornung S., Krill S.L. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior. J. Pharm. Sci. 2006, 96:294-304.
129. Gunawan L., Johari G.P., Shanker R.M. Structural relaxation of acetaminophen glass. Pharm. Res. 2006, 23:967-979.
130. Stanković M., Frijlink H.W., Hinrichs W.L. Polymeric formulations for drug release prepared by hot melt extrusion: application and characterization. Drug Discov. Today 2015, 20:812-823.
131. Nakamichi K., Nakano T., Yasuura H., Izumi S., Kawashima Y. The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int. J. Pharm. 2002, 241:203-211.
132. Breitenbach J., Lewis J. Two concepts, one technology: controlled release and solid dispersion with meltrex. Modified-Release Drug Delivery Technology 2003, 125-134. Marcel Dekker, New York. M.J. Rathbone, J. Hadgraft, M.S. Roberts (Eds.).
133. Loxley A. Devices and implants prepared using hot melt extrusion. Melt Extrusion 2013, 281-298. Springer, New York, USA. M.A. Repka, N. Langley, J. DiNunzio (Eds.).
134. Thybo P., Hovgaard L., Lindeløv J., Brask A., Andersen S. Scaling up the spray drying process from pilot to production scale using an atomized droplet size criterion. Pharm. Res. 2008, 25:1610-1620.
135. Dobry D.E., Settell D.M., Baumann J.M., Ray R.J., Graham L.J., Beyerinck R.A. A model-based methodology for spray-drying process development. J. Pharm. Innov. 2009, 4:133-142.
136. Paudel A., Loyson Y., Van den Mooter G. An investigation into the effect of spray drying temperature and atomizing conditions on miscibility, physical stability, and performance of naproxen-PVP K 25 solid dispersions. J. Pharm. Sci. 2013, 102:1249-1267.
137. Gu B., Linehan B., Tseng Y.C. Optimization of the Büchi B-90 spray drying process using central composite design for preparation of solid dispersions. Int. J. Pharm. 2015, 491:208-217.
138. Tee L.H., Luqman Chuah A., Pin K.Y., Abdull Rashih A., Yusof Y.A. Optimization of spray drying process parameters of Piper betle L. (Sirih) leaves extract coated with maltodextrin. J. Chem. Pharm. Res. 2012, 4:1833-1841.
139. Patel A.S., Soni T., Thakkar V., Gandhi T. Effects of spray drying conditions on the physicochemical properties of the tramadol-hcl microparticles containing Eudragit(®) RS and RL. J. Pharm. Bioallied Sci. 2012, 4:S50-S53.
140. ICH Impurities: guideline for residual solvents Q3C(R5). International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use 2011.
141. Patel B.B., Patel J.K., Chakraborty S., Shukla D. Revealing facts behind spray dried solid dispersion technology used for solubility enhancement. Saudi Pharm. J. 2015, 23:352-365.
142. Al-Obaidi H., Ke P., Brocchini S., Buckton G. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int. J. Pharm. 2011, 419:20-27.
143. Bain D.F., Munday D.L., Smith A. Solvent influence on spray-dried biodegradable microspheres. J. Microencapsul. 1999, 16:453-474.
144. Paluch K.J., Tajber L., Amaro M.I., Corrigan O.I., Healy A.M. Impact of process variables on the micromeritic and physicochemical properties of spray-dried microparticles-part II. Physicochemical characterisation of spray-dried materials. J. Pharm. Pharmacol. 2012, 64:1583-1591.
145. Ní Ógáin O., Tajber L., Corrigan O.I., Healy A.M. Spray drying from organic solvents to prepare nanoporous/nanoparticulate microparticles of protein: excipient composites designed for oral inhalation. J. Pharm. Pharmacol. 2012, 64:1275-1290.
146. Jung J.Y., Yoo S.D., Lee S.H., Kim K.H., Yoon D.S., Lee K.H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 1999, 187:209-218.
147. Dixit M., Kini A.G., Kulkarni P.K. Preparation and characterization of microparticles of piroxicam by spray drying and spray chilling methods. Res. Pharm. Sci. 2010, 5:89-97.
148. Yang Z.Y., Le Y., Hu T.T., Shen Z., Chen J.F., Yun J. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm. Res. 2008, 25:2012-2018.
149. Paidi S.K., Jena S.K., Ahuja B.K., Devasari N., Suresh S. Preparation, in-vitro and in-vivo evaluation of spray-dried ternary solid dispersion of biopharmaceutics classification system class II model drug. J. Pharm. Pharmacol. 2015, 67:616-629.
150. Wang F.J., Wang C.H. Effects of fabrication conditions on the characteristics of etanidazole spray-dried microspheres. J. Microencapsul. 2002, 19:495-510.
151. Sass A., Lee G. Evaluation of some water-miscible organic solvents for spray-drying enzymes and carbohydrates. Drug Dev. Ind. Pharm. 2014, 40:749-757.
152. Morgen M., Bloom C., Beyerinck R., Bello A., Song W., Wilkinson K., Steenwyk R., Shamblin S. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm. Res. 2012, 29:427-440.
153. Ghebremeskel A.N., Vemavarapu C., Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int. J. Pharm. 2007, 328:119-129.
154. Chen J., Ormes J.D., Higgins J.D., Taylor L.S. Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles. Mol. Pharm. 2015, 12:533-541.
155. Marasini N., Tran T.H., Poudel B.K., Cho H.J., Choi Y.K., Chi S.C., Choi H.G., Yong C.S., Kim J.O. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Int. J. Pharm. 2013, 441:424-432.
156. Janssens S., de Armas H.N., Roberts C.J., Van den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J. Pharm. Sci. 2008, 97:2110-2120.
157. Li X., Jiang C., Pan L., Zhang H., Hu L., Li T., Yang X. Effects of preparing techniques and aging on dissolution behavior of the solid dispersions of NF/soluplus/kollidon SR: identification and classification by a combined analysis by FT-IR spectroscopy and computational approaches. Drug Dev. Ind. Pharm. 2015, 41:2-14.
158. Van Goor F.F., Alargova R.G., Alcacio T.E., Arekar S.G., Johnston S.C., Kadiyala I.N., Keshavarz-Shokri A., Krawiec M., Lee E.C., Medek A. Pharmaceutical Compositions and Administrations thereof, Google Patents 2015.
159. Bittorf K.J., Gaspar F., Katstra J.P. Fluidized Spray Drying, Google Patents 2009.
160. Kiekens F.R.I., Voorspoels J.F.M., Baert L.E.C. Process for Preparing Spray Dried Formulations of tmc125, Google Patents 2007.
161. Kulthe V.V., Chaudhari P.D., Aboul-Enein H.Y. Freeze-dried amorphous dispersions for solubility enhancement of thermosensitive API having low molecular lipophilicity. Drug. Res. (Stuttg) 2014, 64:493-498.
162. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006, 58:1688-1713.
163. Seo A., Holm P., Kristensen H.G., Schaefer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int. J. Pharm. 2003, 259:161-171.
164. Aleksić I., Duriš J., Ilić I., Ibrić S., Parojčić J., Srčič S. In silico modeling of in situ fluidized bed melt granulation. Int. J. Pharm. 2014, 466:21-30.
165. Shanmugam S. Granulation techniques and technologies: recent progresses. Bioimpacts 2015, 5:55-63.
166. Passerini N., Albertini B., González-Rodríguez M.L., Cavallari C., Rodriguez L. Preparation and characterisation of ibuprofen-poloxamer 188 granules obtained by melt granulation. Eur. J. Pharm. Sci. 2002, 15:71-78.
167. Gupta M.K., Goldman D., Bogner R.H., Tseng Y.C. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. Pharm. Dev. Technol. 2001, 6:563-572.
168. Kowalski J., Kalb O., Joshi Y.M., Serajuddin A.T. Application of melt granulation technology to enhance stability of a moisture sensitive immediate-release drug product. Int. J. Pharm. 2009, 381:56-61.
169. Rosenberg J., Reinhold U., Liepold B., Berndl G., Breitenbach J., Alani L., Ghosh S. Solid Pharmaceutical Dosage Form, Google Patents 2005.
170. Crowley M.M., Zhang F., Repka M.A., Thumma S., Upadhye S.B., Battu S.K., McGinity J.W., Martin C. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev. Ind. Pharm. 2007, 33:909-926.
171. Wilson M., Williams M.A., Jones D.S., Andrews G.P. Hot-melt extrusion technology and pharmaceutical application. Ther. Deliv. 2012, 3:787-797.
172. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 2002, 54:107-117.
173. Van Melkebeke B., Vervaet C., Remon J.P. Validation of a continuous granulation process using a twin-screw extruder. Int. J. Pharm. 2008, 356:224-230.
174. Alshahrani S.M., Morott J.T., Alshetaili A.S., Tiwari R.V., Majumdar S., Repka M.A. Influence of degassing on hot-melt extrusion process. Eur. J. Pharm. Sci. 2015.
175. Morott J.T., Pimparade M., Park J.B., Worley C.P., Majumdar S., Lian Z., Pinto E., Bi Y., Durig T., Repka M.A. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets. J. Pharm. Sci. 2015, 104:124-134.
176. Brown C., DiNunzio J., Eglesia M., Forster S., Lamm M., Lowinger M., Marsac P., McKelvey C., Meyer R., Schenck L., Terife G., Troup G., Smith-Goettler B., Starbuck C. Hot-melt extrusion for solid dispersions: composition and design considerations. Amorphous Solid Dispersions 2014, 197-230. Springer, New York, USA. N. Shah, H. Sandhu, D.S. Choi, H. Chokshi, A.W. Malick (Eds.).
177. Sakai T., Thommes M. Investigation into mixing capability and solid dispersion preparation using the DSM Xplore Pharma Micro Extruder. J. Pharm. Pharmacol. 2014, 66:218-231.
178. Sotthivirat S., McKelvey C., Moser J., Rege B., Xu W., Zhang D. Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364. Int. J. Pharm. 2013, 452:73-81.
179. Yang Z., Nollenberger K., Albers J., Craig D., Qi S. Microstructure of an immiscible polymer blend and its stabilization effect on amorphous solid dispersions. Mol. Pharm. 2013, 10:2767-2780.
180. Liu X., Lu M., Guo Z., Huang L., Feng X., Wu C. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm. Res. 2012, 29:806-817.
181. Sakurai A., Sakai T., Sako K., Maitani Y. Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug: physicochemical characterization and in vivo study. Chem. Pharm. Bull.(Tokyo) 2012, 60:459-464.
182. Alshehri S.M., Park J.B., Alsulays B.B., Tiwari R.V., Almutairy B., Alshetaili A.S., Morott J., Shah S., Kulkarni V., Majumdar S., Martin S.T., Mishra S., Wang L., Repka M.A. Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via molecular interaction produced by hot melt extrusion technology. J. Drug Delivery Sci. Technol. 2015, 27:18-27.
183. Agrawal A.M., Dudhedia M.S., Patel A.D., Raikes M.S. Characterization and performance assessment of solid dispersions prepared by hot melt extrusion and spray drying process. Int. J. Pharm. 2013, 457:71-81.
184. Lang B., Liu S., McGinity J.W., Williams R.O. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions. Drug Dev. Ind. Pharm. 2015, 1-17.
185. Fule R., Amin P. Development and evaluation of lafutidine solid dispersion via hot melt extrusion: investigating drug-polymer miscibility with advanced characterisation. Asian J. Pharm. Sci. 2014, 9:92-106.
186. Djuris J., Ioannis N., Ibric S., Djuric Z., Kachrimanis K. Effect of composition in the development of carbamazepine hot-melt extruded solid dispersions by application of mixture experimental design. J. Pharm. Pharmacol. 2014, 66:232-243.
187. Wang W., Kang Q., Liu N., Zhang Q., Zhang Y., Li H., Zhao B., Chen Y., Lan Y., Ma Q., Wu Q. Enhanced dissolution rate and oral bioavailability of Ginkgo biloba extract by preparing solid dispersion via hot-melt extrusion. Fitoterapia 2015, 102:189-197.
188. Ghebremeskel A.N., Vemavarapu C., Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm. Res. 2006, 23:1928-1936.
189. Verreck G., Decorte A., Heymans K., Adriaensen J., Cleeren D., Jacobs A., Liu D., Tomasko D., Arien A., Peeters J., Rombaut P., Van den Mooter G., Brewster M.E. The effect of pressurized carbon dioxide as a temporary plasticizer and foaming agent on the hot stage extrusion process and extrudate properties of solid dispersions of itraconazole with PVP-VA 64. Eur. J. Pharm. Sci. 2005, 26:349-358.
190. Verreck G., Decorte A., Heymans K., Adriaensen J., Liu D., Tomasko D.L., Arien A., Peeters J., Rombaut P., Van den Mooter G., Brewster M.E. The effect of supercritical CO2 as a reversible plasticizer and foaming agent on the hot stage extrusion of itraconazole with EC 20 cps. J. Supercrit. Fluids 2007, 40:153-162.
191. Joshi Y., Kowalski J., Lakshman J.P., Royce A.E., Tong W.Q., Vasanthavada M. Formulation, Google Patents 2011.
192. Fang L.Y., Harris D., Krishna G., Moton A.E., Prestipino R.C., Steinman M., Wan J., Waskin H.A. Oral Pharmaceutical Compositions In A Solid Dispersion Comprising Preferably Posaconazole And HPMCAs, Google Patents 2015.
193. Miller J.M., Morris J.B., Sever N.E., Schmitt E.A., GAO P.X., Shi Y., Gao Y., Liepold B., MOOSMANN A., Pauli M. Solid Antiviral Dosage Forms, Google Patents 2015.
194. Surwase S.A., Itkonen L., Aaltonen J., Saville D., Rades T., Peltonen L., Strachan C.J. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension. Eur. J. Pharm. Biopharm. 2015, 96:32-43.
195. Knopp M.M., Olesen N.E., Holm P., Langguth P., Holm R., Rades T. Influence of polymer molecular weight on drug-polymer solubility: a comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer. J. Pharm. Sci. 2015, 104:2905-2912.
196. Forster A., Hempenstall J., Tucker I., Rades T. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int. J. Pharm. 2001, 226:147-161.